Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 6/20 | 0.53 |
| ▸ | PPARG | P37231 | 5/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | CTSK | P43235 | 6/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311165 | 1.00 | ACE (0.59) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL1529592 | 1.00 | ACE (0.59) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL15109826 | 0.90 | CA2 (0.61) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL7850273 | 0.90 | CA2 (0.61) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL6898394 | 0.90 | CA2 (0.61) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL9957484 | 0.89 | PTPN1 (0.58) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL16095718 | 0.89 | PTPN1 (0.58) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL2265571 | 0.89 | PTPN1 (0.58) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL6276560 | 0.89 | ACE (0.56) | ACEITGB3ITGA2BCTSLPTPN1 | |
| SCHEMBL5893305 | 0.89 | ACE (0.56) | ACEITGB3ITGA2BCTSLPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| US-20200383327-A1 | METHOD OF IMPROVING PLANT PERFORMANCE | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2020-12-10 | — | — | US | disclosed |
| US-20190246639-A1 | METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCHORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2019-08-15 | — | — | US | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110014226-A1 | HIGH THROUGHPUT PROTEIN INTERACTION ASSAY | MERCK SHARP & DOHME CORP. | 2011-01-20 | — | — | US | disclosed |
| US-7855292-B2 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-05 | — | — | US | disclosed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008017852-A1 | DIAMINE-CONTAINING, TETRA- SUBSTITUTED PIPERAZINE COMPOUNDS AS MELANOCORTIN RECEPTOR MODULATORS | PALATIN TECHNOLOGIES, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-7297816-B2 | Sulfonamide compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-20 | — | — | US | disclosed |
| EP-1797083-A1 | SULFONAMIDE COMPOUNDS | Janssen Pharmaceutica, N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132511-A1 | Cholecystokinin (CCK) receptor ligands; antagonists; 3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-propionic acid methy; pain, drug dependence, anxiety, panic attack, schizophrenia, pancreatic disorders, secretory disorders, ulcers, cancers; improved pharmacokinetics | CCKAR, CCKBR, GRPR | ACE 3431/4885ITGB3 4395/4885ITGA2B 3727/4885 |
| US-20110014226-A1 | HIGH THROUGHPUT PROTEIN INTERACTION ASSAY | SSB, AIP, LY96 | ACE 2422/4885ITGB3 4274/4885ITGA2B 4105/4885 |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | NPY1R, MC5R, MC4R | ACE 3623/4885ITGB3 4255/4885ITGA2B 2812/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | ACE 3310/4885ITGB3 4335/4885ITGA2B 3630/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | ACE 3146/4885ITGB3 4856/4885ITGA2B 4329/4885 |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | MC4R, MC1R, MC5R | ACE 3994/4885ITGB3 1892/4885ITGA2B 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.